Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Stomach Cancer

Aliases
Gastric Carcinoma

417 clinical trials

479 products

53 drugs

3 abstracts

Product
AB308
Product
pembrolizumab
Clinical trial
A Phase 1 Study of SGN-PDL1V in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-31
Clinical trial
A Phase 2 Non-randomized, Open-label, Multi-cohort, Multi-center Study Assessing the Clinical Benefit of SAR444245 (THOR-707) Combined With Other Anticancer Therapies for the Treatment of Participants With Advanced and Metastatic Gastrointestinal Cancer
Status: Active (not recruiting), Estimated PCD: 2023-07-26
Product
SGN-PDL1V
Product
Zimberelimab
Product
THOR-707
Product
Pembrolizumab
Product
Cetuximab
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2025-01-01
Product
zolbetuximab
Product
oxaliplatin
Product
leucovorin
Product
fluorouracil
Clinical trial
A Phase 2 Study of Zolbetuximab (IMAB362) as Monotherapy and in Combination With Chemotherapy and/or Immunotherapy in Subjects With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and Locoregional Gastric or GEJ Adenocarcinoma Whose Are Claudin (CLDN) 18.2 Positive
Status: Recruiting, Estimated PCD: 2025-04-30
Product
nivolumab
Product
Folinic acid
Product
Docetaxel
Product
CPL304110
Clinical trial
A Phase I, Open-label, Multicentre, Dose Escalation Study to Assess Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2024-06-01
Product
NGM831
Clinical trial
A Phase 1 Dose Escalation/Dose Finding Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Product
NGM831 and NGM438 plus pembrolizumab
Clinical trial
A Phase 1 Dose-escalation and Expansion Study of the PD-1 x ILT4 Bispecific Antibody CDX-585 in Patients With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2024-12-01
Product
CDX-585
Clinical trial
nextHERIZON: An Open-Label, Signal Generating, Phase 2 Study of HER-Vaxx in Combination With Chemotherapy or Pembrolizumab in Patients With Metastatic HER2/Neu Over-Expressing Gastric or Gastroesophageal Junction (GEJ) Adenocarcinomas Who Have Previously Received Trastuzumab and Progressed on This Treatment
Status: Active (not recruiting), Estimated PCD: 2024-03-31
Product
Ramucirumab + Paclitaxel
Product
IMU-131
Clinical trial
A Phase III, Open-labelled, Randomised Study of Neoadjuvant Docetaxel+Oxaliplatin+S-1 (DOS) + Surgery + Adjuvant S-1 Versus Surgery + Adjuvant S-1 in Patients With Resectable Advanced Gastric Cancer
Status: Completed, Estimated PCD: 2019-01-21
Product
Oxaliplatin
Product
S-1
Clinical trial
A Phase Ib/II Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients With Advanced Solid Tumor
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1 Study of the Safety and Efficacy of CRX100 as Monotherapy and in Combination With Pembrolizumab in Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Fludarabine
Clinical trial
FIGHT: A Phase 3 Randomized, Double-Blind, Controlled Study Evaluating FPA144 and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Cancer: Phase 2 Preceded by Dose Finding in Phase 1
Status: Completed, Estimated PCD: 2019-01-31
Product
Bemarituzumab
Product
FOLFOX6
Clinical trial
A Phase 1 Dose Escalation Trial to Determine the Safety, Tolerance, Maximum Tolerated Dose, and Preliminary Antineoplastic Activity of IKS014, a HER2-Targeting Antibody Drug Conjugate (ADC), in Participants With Advanced HER2+ Solid Tumors
Status: Recruiting, Estimated PCD: 2025-09-01
Product
MDX2001
Product
IKS014
Clinical trial
A Phase 1/2a, Multicenter, First-in-human, Open-label Clinical Trial Evaluating MDX2001 Monotherapy in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2028-08-01
Clinical trial
A Phase 1/2 Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Product
CRX100
Product
Cyclophosphamide
Product
LUM015
Clinical trial
Study of 89Zr-girentuximab for PET Imaging of Solid Tumors Likely to Express High Levels of CAIX
Status: Recruiting, Estimated PCD: 2025-12-08
Clinical trial
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Surufatinib and Tislelizumab
Product
Atezolizumab
Clinical trial
A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) and Trastuzumab in Combination With Capecitabine and Oxaliplatin (Xelox) in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (GEJ)
Status: Active (not recruiting), Estimated PCD: 2023-05-08
Product
TORL-2-307-MAB
Clinical trial
A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2022-09-13
Product
89Zr-DFO-girentuximab
Product
E-602
Product
Capecitabine
Clinical trial
Clinical Study of CLDN18.2-targeting Chimeric Antigen Receptor-modified Autologous T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression
Status: Recruiting, Estimated PCD: 2024-12-01
Product
TRK-950
Product
Claudin 18.2 CAR-T
Clinical trial
A Phase 2/3 Trial to Evaluate Margetuximab in Combination With INCMGA00012 and Chemotherapy or MGD013 and Chemotherapy in Patients With Metastatic or Locally Advanced, Treatment-naïve, HER2-Positive Gastric or Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Product
Tebotelimab
Product
CEA-targeted CAR-T cells
Clinical trial
Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
margetuximab
Product
Retifanlimab
Product
FOG-001
Clinical trial
A Phase 1/2 Study of FOG-001 in Participants With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2027-04-01
Product
TORL-2-307-ADC
Product
TT-00420
Clinical trial
A Phase 1/2, Open-Label, Single-Arm, Dose-Escalation and Dose-Expansion Study of the Safety, Tolerability, Pharmacokinetic, and Antitumor Activity of E-602 as a Single Agent and in Combination With Cemiplimab in Patients With Advanced Cancers
Status: Recruiting, Estimated PCD: 2025-06-01
Product
CDX-1140
Clinical trial
A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-ADC in Participants With Advanced Cancer
Status: Recruiting, Estimated PCD: 2025-01-15
Clinical trial
A Phase 1/2 Open Label, Dose Escalation and Expansion Study of MDNA11, IL-2 Superkine, Administered Alone or in Combination With Immune Checkpoint Inhibitor in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-06-30
Product
Nab-Paclitaxel
Product
BA3071
Clinical trial
A Phase 1/2 Study of BA3071 as Monotherapy and in Combination With a PD-1 Blocking Antibody in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-30
Product
Nivolumab
Product
MDNA11
Product
CBX-12
Product
NGM831 plus Pembrolizumab
Product
Chemotherapy
Product
SHR-A1811
Clinical trial
Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of SHR-A1811, in Patients With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer: a Phase 1 Study
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies
Status: Recruiting, Estimated PCD: 2024-11-01
Product
RC48-ADC
Clinical trial
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG).
Status: Recruiting, Estimated PCD: 2024-05-30
Product
CDX-301
Product
Leucovorin
Clinical trial
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
RC98
Product
Irinotecan
Product
177Lu-3BP-227
Clinical trial
A Phase 1, First in Human, Dose-Escalation Study of TORL-2-307-MAB in Participants With Advanced Cancer
Status: Recruiting, Estimated PCD: 2024-12-15
Clinical trial
A Phase II Study of Perioperative Disitamab Vedotin Plus Toripalimab and XELOX Versus Disitamab Vedotin Plus Toripalimab Versus XELOX in Subjects With HER2-expressing Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.
Status: Recruiting, Estimated PCD: 2025-01-31
Product
Disitamab Vedotin
Product
Toripalimab
Clinical trial
A Phase II Clinical Study to Evaluate the Efficacy and Safety of SI-B003 Monotherapy and BL-B01D1+SI-B003 Combination Therapy (BL-B01D1+SI-B003) in Patients With Locally Advanced or Metastatic Esophageal Cancer, Gastric Cancer, Colorectal Cancer and Other Gastrointestinal Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
SI-B003
Product
BL-B01D1
Clinical trial
An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1
Status: Terminated, Estimated PCD: 2020-04-03
Product
Cabotamig
Product
AB122
Clinical trial
Platform Study of AB122 Based Treatments in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-05-01
Product
TAS-116
Product
ONC-392
Clinical trial
A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Safety, Pharmacokinetics (PK), and Efficacy of ONC-392 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumors and NSCLC: An Open Label Phase IA/IB Study. Preserve CTLA4 Checkpoint Function (PRESERVE-001)
Status: Recruiting, Estimated PCD: 2024-06-30
Product
NC410
Product
5-FU
Product
Cisplatin
Product
Ramucirumab
Clinical trial
Phase 1/2 Study of TAS-120 in Patients With Advanced Solid Tumors Harboring FGF/FGFR Aberrations
Status: Completed, Estimated PCD: 2020-10-01
Product
Futibatinib
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Status: Terminated, Estimated PCD: 2023-07-07
Product
Gemcitabine
Product
Carboplatin
Product
Paclitaxel
Product
Cemiplimab
Clinical trial
A Phase 2 Study to Assess the Safety, Efficacy of FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
Status: Completed, Estimated PCD: 2023-10-17
Clinical trial
Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
MCLA-158
Product
FLX475
Product
TAS-120
Product
TAS-115
Product
TAS-102
Clinical trial
A Phase 1/1b Dose Escalation/Expansion Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Phase IIb, Clinical Trial to Study the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as a First Line Chemotherapy in Participants With Advanced or Recurrent Gastric Cancer (KEYNOTE-659)
Status: Completed, Estimated PCD: 2021-05-30
Product
Bevacizumab
Clinical trial
TRASTUZUMAB BS for Intravenous Infusion 60 mg [Pfizer], TRASTUZUMAB BS for Intravenous Infusion 150 mg [Pfizer] General Investigation (Unresectable Advanced/Recurrent HER2-Overexpressing Gastric Cancer)
Status: Active (not recruiting), Estimated PCD: 2025-09-08
Clinical trial
A Phase 1, Multicenter, Open-label, Multiple Dose-escalation and Expansion Study of ARX788, as Monotherapy in Advanced Solid Tumors With HER2 Expression
Status: Completed, Estimated PCD: 2023-09-13
Product
NGM438
Clinical trial
A Phase 1/2a Study Utilizing 64Cu-LNTH-1363S (64Cu Radiolabeled FAPi PET/CT Imaging Agent) in Patients With Sarcoma or Gastrointestinal Tract Cancer (PHANTOM Trial)
Status: Not yet recruiting, Estimated PCD: 2025-11-01
Product
Imiquimod
Product
PLD
Product
ARX788
Product
MAGE-A4ᶜ¹º³²T cells
Clinical trial
A Single Arm, Open Lable, Dose Escalation Phase I Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Preliminary Efficacy of KN026 Monotherapy in Patients With HER2-positive Advanced Malignant Breast and Gastric Cancer
Status: Completed, Estimated PCD: 2022-06-30
Product
KN026
Product
64Cu-LNTH-1363S
Product
TS-1
Product
NKT3447
Clinical trial
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Orally Available CDK2 Inhibitor NKT3447 in Adults With Advanced/Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Taxotere
Clinical trial
A Multicenter, Randomized, Controlled Phase III Clinical Study of Docetaxel for Injection (Albumin-bound) Versus Taxotere in Gastric Cancer
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Clinical trial
Phase 1 Dose Escalation, Multi-tumor Study to Assess the Safety, Tolerability and Antitumor Activity of Genetically Engineered MAGE-A4ᶜ¹º³²T in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Status: Active (not recruiting), Estimated PCD: 2022-12-27
Product
CHM-2101
Product
ZW25
Clinical trial
Phase 1b/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2023-12-07
Product
CT041
Product
Tislelizumab
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Dose-Expansion, Phase 1/2 Study of BBI-355 and BBI-355 in Combination With Select Targeted Therapies in Subjects With Locally Advanced or Metastatic Solid Tumors With Oncogene Amplifications
Status: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Randomized，Multicenter, Open-Label，Phase II/III Study to Evaluate the Safety and Efficacy of Disitamab Vedotin Combined With Cadonilimab in Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Who Have Progressed on r First-line Therapy
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Infigratinib
Product
Cadonilimab
Clinical trial
A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.
Status: Recruiting, Estimated PCD: 2025-11-01
Product
FerroTrace
Product
BBI-355
Clinical trial
A Phase 1a/1b Study to Evaluate the Safety and Tolerability of STK-012 Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
DKN-01
Product
STK-012
Product
Fluorouracil
Clinical trial
A Phase II, Multicenter, Open-Label, Single Arm Study of Oral Infigratinib Monotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma, Who Harboring FGFR2 Gene Amplification
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
FIGHT: A Phase 2 Randomized, Double-Blind, Controlled Study Evaluating Bemarituzumab (FPA144) and Modified FOLFOX6 in Patients With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Preceded by Dose-Finding in Phase 1
Status: Completed, Estimated PCD: 2020-09-23
Product
Placebo
Clinical trial
Magnetic Sentinel Lymph Node Mapping in Upper Gastro-Intestinal Cancer: A Feasibility Clinical Investigation
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Erlotinib
Clinical trial
Open-label, Multicenter, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologous Anti-claudin 18.2 Chimeric Antigen Receptor T-cell Therapy in Subjects With Advanced Gastric, Pancreatic, or Other Specified Digestive System Cancers
Status: Active (not recruiting), Estimated PCD: 2025-06-01
Product
[225]-FPI-2059
Clinical trial
A Phase 1 Study of [225Ac]-FPI-2059 in Adult Participants With NTSR1-Expressing Advanced, Metastatic and/or Recurrent Solid Tumours
Status: Recruiting, Estimated PCD: 2025-06-01
Product
BLU-222
Clinical trial
A Phase 1/2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of BLU-222 as a Single Agent and in Combination Therapy for Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-11-30
Product
Ribociclib
Product
Fulvestrant
Product
[111In]-FPI-2058
Clinical trial
A Randomized, Double-blinded, Placebo Controlled, Multicentre Phase III Study to Assess the Efficacy and Safety of Olaparib (AZD2281) in Combination With Paclitaxel, Compared to Placebo in Combination With Paclitaxel, in Asian Patients With Advanced Gastric Cancer (Including the Gastro-oesophageal Junction) Who Have Progressed Following First Line Therapy
Status: Completed, Estimated PCD: 2016-04-04
Product
Olaparib
Product
TST001
Clinical trial
A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Product
mFOLFOX6
Product
Albumin-Bound Paclitaxel
Product
Claudin 18.2
Clinical trial
A Phase 1B/2, Open-label Study of Q702 in Combination With Intravenous Pembrolizumab in Patients With Selected Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-10-30
Product
Q702
Product
DNX-2440
Clinical trial
A Phase I Safety and Window-of-opportunity Study of Preoperative Intratumoral Injection of OX40-ligand Expressing Oncolytic Adenovirus (DNX-2440) in Patients With Resectable Liver Metastasis
Status: , Estimated PCD: 2026-07-31
Product
Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
Clinical trial
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-05-01
Product
MGC026
Clinical trial
A Phase 1b/3 Study of Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab Alone in Subjects With Previously Untreated Advanced Gastric and Gastroesophageal Junction Cancer With FGFR2b Overexpression
Status: Recruiting, Estimated PCD: 2026-09-26
Clinical trial
A Randomized Phase 2 Study to Evaluate Safety and Efficacy of the Combination of SHR-1210 With Capecitabine + Oxaliplatin or Apatinib as First-line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Completed, Estimated PCD: 2020-11-25
Clinical trial
An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-02-02
Product
INBRX-106
Product
Allogeneic NK
Clinical trial
A Phase II, Single-Arm Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
Status: Terminated, Estimated PCD: 2023-11-17
Product
Tiragolumab
Clinical trial
An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients
Status: Withdrawn, Estimated PCD: 2025-06-30
Clinical trial
A Phase 1b/2 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2-expressing Gastric Cancer (DESTINY-Gastric-03)
Status: Recruiting, Estimated PCD: 2026-07-30
Product
Durvalumab
Product
Trastuzumab deruxtecan
Product
Rilvegostomig
Product
SHR-1210
Product
Volrustomig
Clinical trial
A Phase 3, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)
Status: Recruiting, Estimated PCD: 2024-04-15
Product
TOS-358
Clinical trial
A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K)-Alpha Inhibitor, TOS-358, in Adult Subjects With Select Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
AZD0901
Product
5-Fluorouracil
Clinical trial
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Tumours Expressing Claudin 18.2.
Status: Recruiting, Estimated PCD: 2025-05-02
Product
Nanoliposomal Irinotecan
Product
l-leucovorin
Product
Leucovorin Calcium
Product
Apatinib
Clinical trial
A Phase 1/2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SNS-101 (Anti VISTA) as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2027-06-01
Product
HC-5404-FU
Product
SNS-101
Product
Zolbetuximab
Clinical trial
A Multicenter, Open-label, Phase 1a Study of HC-5404-FU in Subjects With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2023-12-07
Clinical trial
A Phase 1 Open-label Study of IMAB362 in Japanese Subjects With Locally Advanced or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma
Status: Completed, Estimated PCD: 2020-06-09
Product
AZD7789
Product
NGM831 plus pembrolizumab
Product
NGM831 and NGM438 plus Pembrolizumab
Clinical trial
A Multicenter Open-label Phase 1/1b Study to Evaluate the Safety and Preliminary Efficacy of SO-C101 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced/Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-08-01
Clinical trial
An Open-label, Dose Escalation and Expansion, Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of TAK-500, a Novel Stimulator of Interferon Genes Agonist, as a Single Agent and in Combination With Pembrolizumab in Adult Patients With Select Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-08-11
Product
TAK-500
Product
HER3-DXd
Clinical trial
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors.
Status: Recruiting, Estimated PCD: 2025-07-29
Product
Ramucirumab plus Paclitaxel
Clinical trial
A Phase Ia/Ib, Open Label, Multicenter, Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-31
Product
RO7502175
Clinical trial
A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of KY1044 as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies
Status: Active (not recruiting), Estimated PCD: 2024-08-05
Product
KY1044
Product
KY1044 and Atezolizumab
Product
SO-C101
Clinical trial
A Phase I, Open Label, Dose-Escalation, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AUR106 in Patients With Select Relapsed Advanced Malignancies (JIVAN)
Status: Recruiting, Estimated PCD: 2025-05-01
Clinical trial
A Randomized, Multi-center, Double-blind, Placebo-controlled Phase 3 Study of Bemarituzumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer With FGFR2b Overexpression
Status: Recruiting, Estimated PCD: 2025-08-18
Product
AUR106
Clinical trial
A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-07265028 AS A SINGLE AGENT AND IN COMBINATION WITH SASANLIMAB EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTI-TUMOR ACTIVITY OF PF-07265028 IN PARTICIPANTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Terminated, Estimated PCD: 2023-10-16
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 2 Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer
Status: Recruiting, Estimated PCD: 2025-08-31
Product
HFB200301
Clinical trial
An Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-09-30
Product
FOLFOX
Product
XELOX
Product
CAPOX
Product
SOX
Clinical trial
A Phase 1b/2 Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of Bemarituzumab in Combination With Other Anti-cancer Therapies in Subjects With Previously Untreated Advanced Gastric or Gastroesophageal Junction Cancer (FORTITUDE-103).
Status: Recruiting, Estimated PCD: 2026-03-17
Clinical trial
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200301 (TNFR2 Agonist Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-01
Product
LB1908
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion, Multicenter Study of Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-07-01
Product
PF-07265028
Product
Sasanlimab
Product
PF-06940434
Product
PF-06801591
Clinical trial
A PHASE 1 STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ESCALATING DOSES OF PF-06940434 IN PATIENTS WITH ADVANCED OR METASTATIC SOLID TUMORS
Status: Active (not recruiting), Estimated PCD: 2024-08-30
Product
NGM831 + Pembrolizumab
Product
RO7496353
Clinical trial
A Phase Ib, Open-Label, Multicenter Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7496353 in Combination With a Checkpoint Inhibitor With or Without Standard-of-Care Chemotherapy in Patients With Locally Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-30
Product
Nab-paclitaxel
Clinical trial
A Multicenter, Open-label, Phase 1/2 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2027-04-01
Clinical trial
A Randomized, Double-blinded，Multicenter，Phase II Clinical Study of HLX22 (Recombinant Humanized Anti-HER2 Monoclonal Antibody Injection) in Combination With Trastuzumab and Chemotherapy (XELOX) Versus Placebo in Combination With Trastuzumab and Chemotherapy (XELOX) for Treatment of Locally Advanced or Metastatic Gastric Cancer (GC)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
HLX22
Product
AB-201
Product
AZD5305
Clinical trial
A Modular Phase I/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2026-12-15
Product
T- Dxd
Product
Camizestrant
Product
MNPR-101-DFO*-89Zr PET Scan
Clinical trial
A Phase 1/1b Open-label, First-in-human, Single Agent, Dose Escalation and Expansion Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors.
Status: Terminated, Estimated PCD: 2024-01-15
Product
SAR443216
Clinical trial
Open Label Pilot Study Evaluating Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
Status: Recruiting, Estimated PCD: 2025-04-01
Product
Dato-DXd
Product
ONO-4578
Clinical trial
A Randomized, Multicenter, Double-blind, Phase II Study to Compare the Efficacy and Safety of the Treatment With ONO-4578 in Combination With Nivolumab, Fluoropyrimidine-based and Platinum- Based Chemotherapy (Hereinafter Referred to as Chemotherapy) With Those of the Treatment With Placebo in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Status: Recruiting, Estimated PCD: 2025-11-30
Product
AB011
Product
AZD5863
Clinical trial
A Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD5863, a T Cell-engaging Bispecific Antibody That Targets Claudin 18.2 (CLDN18.2) and CD3 in Adult Participants With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-11
Clinical trial
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Product
5-fluorouracil
Clinical trial
A Phase III, Randomized, Double-Blind, Clinical Trial of Pembrolizumab (MK-3475) Plus Chemotherapy (XP or FP) Versus Placebo Plus Chemotherapy (XP or FP) as Neoadjuvant/Adjuvant Treatment for Subjects With Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (KEYNOTE-585)
Status: Active (not recruiting), Estimated PCD: 2024-02-16
Clinical trial
A Phase 1b/2, Open-Label, Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab for Participants With Advanced Unresectable and/or Metastatic Immune Checkpoint Inhibitor (ICI) Refractory Solid Tumors or ICI Naïve MSS/MSI-Low Solid Tumors
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)
Status: Completed, Estimated PCD: 2022-05-11
Clinical trial
An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression After Prior Fluoropyrimidine and/or Platinum-Containing Chemotherapy
Status:
Product
CMG901
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
A Phase 2/3 Study of Evorpacept (ALX148) in Patients With Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma (ASPEN-06)
Status: Recruiting, Estimated PCD: 2026-07-01
Clinical trial
A 1/2 Phase Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ASKB589 in Combination With CAPOX and Sintilimab in Patients With Advanced, and Unresectable Gastric/Esophagogastric Junction Cancer.
Status: Recruiting, Estimated PCD: 2025-02-10
Product
GZ17-6.02
Product
Evorpacept
Product
Pemigatinib
Clinical trial
A Dose Ascending, Open Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Preliminary Efficacy of VG161 Combined With Nivolumab Injection in Subjects With Metastatic Gastric Cancer
Status: Recruiting, Estimated PCD: 2025-12-01
Product
VE800
Product
Vancomycin
Clinical trial
A Multi-center, Open-label, Phase II Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of Savolitinib in Treating Gastric Cancer and Esophagogastric Junction Adenocarcinoma Patients With MET Gene Amplifications
Status: Recruiting, Estimated PCD: 2025-04-01
Clinical trial
A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Status: Completed, Estimated PCD: 2019-04-30
Product
ADCT-301
Product
ASKB589
Clinical trial
An Open-Label, Phase 1, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of CMG901 in Subjects With Advanced Unresectable or Metastatic Solid Tumor
Status: Recruiting, Estimated PCD: 2024-05-01
Product
LM302+Toripalimab
Product
FT500
Clinical trial
Phase I Clinical Study of Chimeric Antigen Receptor T Cells (C-13-60) in the Treatment of Carcinoembryonic Antigen (CEA) Positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Product
Talimogene Laherparepvec
Product
Recombinant oncolytic herpes simplex virus type 1 (R130)
Product
RAPA-201
Clinical trial
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors (Phase 1)
Status: Completed, Estimated PCD: 2022-11-15
Clinical trial
Phase I/II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of PD-(L)1 Resistant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-01-01
Clinical trial
A Phase I/Ib, Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination With Capecitabine, Given Orally on a Daily Schedule in Patients With Advanced Solid Tumors or Lymphoma
Status: Active (not recruiting), Estimated PCD: 2023-05-01
Clinical trial
A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating Combination of TST001, Nivolumab and Chemotherapy as First-Line Treatment in Subjects With Claudin18.2 Positive Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (Gastric/GEJ) Adenocarcinoma
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Clinical trial
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Status: Completed, Estimated PCD: 2021-08-26
Product
Whole Genomic Methylation and Fragmentation Profile Analysis of cfDNA
Product
Placebo CapOx or mFOLFOX6 and NIVO or (Substudy) Placebo, Oxaliplatin and capecitabine or 5-fluorouracil (5-FU)
Clinical trial
A Phase 2 Study of VLS-101 in Patients With Solid Tumors
Status: Completed, Estimated PCD: 2023-06-12
Product
Bavituximab
Product
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell)
Clinical trial
A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies (FIGHT-101)
Status: Terminated, Estimated PCD: 2021-12-17
Product
Zilovertamab
Product
NGM120
Clinical trial
A Phase 1B Study of Donafenib Monotherapy for Previously Treated Metastatic Gastric Cancer
Status: Terminated, Estimated PCD: 2019-06-13
Product
Milademetan
Clinical trial
A Phase 2, Multicenter Open-label, Non-randomized Study of Bavituximab Plus Pembrolizumab in Patients With Advanced Gastric or Gastroesophageal Cancer Who Have Progressed on or After at Least One Prior Standard Therapy
Status: Completed, Estimated PCD: 2021-12-20
Clinical trial
A Phase 1, Dose Escalation Study of MGAH22 in Patients With Refractory HER2 Positive Breast Cancer and Patients With Other HER2 Positive Carcinomas for Whom No Standard Therapy Is Available
Status: Completed, Estimated PCD: 2022-06-14
Product
Savolitinib
Product
navicixizumab+paclitaxel
Product
navicixizumab+irinotecan
Clinical trial
A Phase II, Open-Label, Multicenter Study Evaluating the Efficacy, Safety, and Tolerability of LM-302 Combined With Toripalimab in CLDN18.2 Positive Patients Advanced Gastro-Intestinal Cancer
Status: Recruiting, Estimated PCD: 2025-07-01
Clinical trial
A Phase 1/2 Dose-Finding Study Followed by Expansion Cohorts of NGM120, a GFRAL Antagonist Monoclonal Antibody Blocking GDF15 Signaling, in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Ipilimumab
Product
Relatlimab
Clinical trial
A Phase I/II Trial in Patients With Metastatic Gastrointestinal Epithelial Cancer Administering Tumor-Infiltrating Lymphocytes in Which the Gene Encoding CISH Was Inactivated Using the CRISPR/Cas9 System
Status: Recruiting, Estimated PCD: 2023-09-01
Clinical trial
A Phase 1b/2Study of Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss (MANTRA-4)
Status: Withdrawn, Estimated PCD: 2023-05-30
Product
Donafenib
Clinical trial
A Phase 1b, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Camidanlumab Tesirine (ADCT-301) as Monotherapy or in Combination in Patients With Selected Advanced Solid Tumors
Status: Terminated, Estimated PCD: 2022-12-08
Clinical trial
Development and Validation of a Blood-based Assay for Gastric Cancer Early Detection Using Multi-dimensional Analysis of Cell Free DNA Whole Methylome Sequencing-Protocol for an Observational, Case-control Study
Status: Recruiting, Estimated PCD: 2024-03-31
Product
BMS-986205
Product
Rucaparib
Product
Tumor-Infiltrating Lymphocytes
Product
Aldesleukin
Product
OB-002
Clinical trial
A Phase 2, Multicenter, Open-Label Basket Study of Navicixizumab Monotherapy or in Combination With Paclitaxel or Irinotecan in Patients With Select Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-04-15
Product
RGX-202-01
Clinical trial
A Phase 1 Study of RGX-202-01 (Ompenaclid) , a Small Molecule Inhibitor of the Creatine Transporter SLC6a8, as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies With Select Expansion Cohorts
Status: Recruiting, Estimated PCD: 2023-12-31
Product
IL-2
Clinical trial
An Open, Two-stage, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AB011 Injection in Patients With CLDN18.2-positive Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-07-27
Clinical trial
A Phase 1b, Open-label, Non-randomized Trial for the Assessment of Safety, Tolerability, and Pharmacokinetics of OB-002 as a Monotherapy in Patients With Refractory Metastatic Colorectal, Pancreatic, Gastric, Breast, or Urothelial Cancer
Status: Not yet recruiting, Estimated PCD: 2025-04-01
Product
FOLFIRI
Clinical trial
A Clinical Safety and Efficacy Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-02
Product
Lenvatinib
Clinical trial
A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects With Selected Solid Tumors (LEAP-005)
Status: Active (not recruiting), Estimated PCD: 2024-12-20
Product
Navicixizumab
Clinical trial
A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Product
NGM707
Clinical trial
A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
Status: Recruiting, Estimated PCD: 2025-02-01
Product
BBI608
Clinical trial
A Phase III Clinical Trial of BBI608 Plus Weekly Paclitaxel vs. Placebo Plus Weekly Paclitaxel in Adult Patients With Advanced, Previously Treated Gastric and Gastro-Esophageal Junction Adenocarcinoma
Status: Completed, Estimated PCD: 2017-09-20
Clinical trial
Phase I/IIa, First-in-human, Open-label, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of BNT141 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With CLDN18.2-positive Solid Tumors
Status: Terminated, Estimated PCD: 2023-07-24
Clinical trial
Expanded Access Use of DKN-01 for the Treatment of Advanced Solid Tumors
Status:
Product
TST001, CapOx or mFOLFOX6 and NIVO or TST001, Oxaliplatin and capecitabine or 5-fluorouracil
Clinical trial
An Open-Label Study to Assess the Safety, Tolerability, and Efficacy of Active Immunotherapy With Dose Escalation and Cohort Expansion of OBI-833 (Globo H-CRM197) in Advanced/Metastatic Gastric, Lung, Colorectal, or Breast Cancer Subjects
Status: Completed, Estimated PCD: 2020-12-22
Clinical trial
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-03-30
Clinical trial
Phase IIa Open-label Clinical Study of Intratumoural Administration of BO-112 in Combination With Pembrolizumab in Subjects With Liver Metastasis From Colorectal Cancer or Gastric/Gastro-oesophageal Junction Cancer
Status: Terminated, Estimated PCD: 2022-12-02
Product
NK510
Clinical trial
Exploratory Study of NK510 Cell Therapy Combined With Monoclonal Antibody in the Treatment of Recurrent and Refractory Advanced Gastric Cancer
Status: , Estimated PCD: 2024-11-01
Clinical trial
Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (Formerly Known as CB1158) as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
Status: Completed, Estimated PCD: 2020-08-31
Clinical trial
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
OBI-833/OBI-821
Product
BO-112
Product
BNT141
Clinical trial
Chimeric Antigen Receptor T Lymphocytes (CAR-T) Targeting CEA in the Treatment of CEA Positive Clinical Study of Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
AI-061
Product
INCB001158
Clinical trial
A Phase 2 Multi-arm, Open Label Study to Assess the Safety and Efficacy of EP0057 in Combination With Olaparib in Defined Populations of Patients With Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer
Status: Withdrawn, Estimated PCD: 2024-08-01
Clinical trial
A Phase 1 Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Paclitaxel in Patients With Advanced Gastric Cancer
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Phase 1/2, Open-label, Multicenter Study of the Combination of NKTR-214 and Nivolumab or the Combination of NKTR-214, Nivolumab, and Other Anti-Cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
Status: Completed, Estimated PCD: 2022-04-28
Product
NKTR-214 + Nivolumab + Ipilimumab
Product
NGM707 plus Pembrolizumab
Product
EP0057
Product
NKTR-214 + Nivolumab
Product
APL-101
Product
Minnelide
Product
RAIN-32
Clinical trial
Efficacy and Safety Evaluation of Sintilimab or Placebo in Combination With XELOX as First Line Treatment in Patients With Gastric Cancer
Status: Completed, Estimated PCD: 2021-06-20
Product
placebo
Clinical trial
First-in-human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety of GEN1029 in Patients With Malignant Solid Tumors
Status: Terminated, Estimated PCD: 2021-10-12
Clinical trial
A Phase 2 Basket Study of Milademetan in Advanced/Metastatic Solid Tumors (MANTRA-2)
Status: Terminated, Estimated PCD: 2023-10-15
Clinical trial
A Phase 1B/2A Study of the Safety, Tolerability and Initial Efficacy of Oral AMXT 1501 Dicaprate and Intravenous Difluoromethylornithine (DFMO) in Patients With Cancer
Status: Recruiting, Estimated PCD: 2024-06-30
Clinical trial
Phase 1/2 Dose Escalation and Expansion Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
Status: Recruiting, Estimated PCD: 2024-04-01
Clinical trial
QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
N-803
Product
N-803 + Pembrolizumab + PD-L1 t-haNK
Clinical trial
A Phase 1 Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies
Status: Completed, Estimated PCD: 2023-04-06
Product
MCLA-129
Product
GEN1029
Product
CEA CAR-T cells
Product
CCT303-406
Product
olaparib
Product
paclitaxel
Clinical trial
A Randomised, Double Blinded, Multicentre Phase II Study to Assess the Efficacy of Olaparib (AZD2281, KU-0059436) in Combination With Paclitaxel Versus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer Who Progress Following First-line Therapy
Status: Completed, Estimated PCD: 2012-05-11
Product
AVM0703
Clinical trial
AVM0703-EAP
Status:
Product
CDX-527
Product
Sintilimab
Product
Hydrocortisone
Product
Proton pump inhibitor
Clinical trial
Clinical Study of CEA-Targeted CAR-T Therapy in Patients With Relapsed and Refractory CEA+ Cancer
Status: , Estimated PCD: 2023-12-31
Clinical trial
A Phase I Trial to Assess Safety, Tolerability and Anti-tumor Activity of Autologous T Cell Modified Chimeric Antigen Receptor (CAR) (CCT303-406) in Patients With Relapsed or Refractory HER2 Positive Solid Tumors
Status: Recruiting, Estimated PCD: 2024-03-29
Product
Osimertinib
Product
N-803 + Pembrolizumab
Product
N-803 + Nivolumab
Product
N-803 + Atezolizumab
Product
N-803 + Avelumab
Clinical trial
A Phase I, Open-label Clinical Trial to Evaluate Safety, Tolerability, Antitumor Activities and Pharmacokinetics of IN10018 as Mono or Combination Therapy in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Completed, Estimated PCD: 2021-12-03
Clinical trial
A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-09-15
Product
AMXT1501
Product
DFMO
Product
IN10018
Product
QBS10072S
Clinical trial
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
Status: Completed, Estimated PCD: 2022-09-21
Product
N-803 + Nivolumab + PD-L1 t-haNK
Product
N-803 + Atezolizumab + PD-L1 t-haNK
Product
N-803 + Avelumab + PD-L1 t-haNK
Product
[225Ac]-FPI-1966
Product
[111In]-FPI-1967
Product
vofatamab
Clinical trial
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours
Status: Terminated, Estimated PCD: 2023-09-08
Clinical trial
Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France
Status:
Product
cabozantinib
Product
atezolizumab
Product
GEN-001
Product
Avelumab
Product
AST-301
Clinical trial
A Phase 2 Study to Evaluate the Safety and Immunological Efficacy of Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With HER2 Expressing Gastric Cancer (CORNERSTONE-003)
Status: Recruiting, Estimated PCD: 2023-10-15
Product
KVA12123
Clinical trial
A Phase 1/2 Open-label Trial of KVA12123 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-30
Product
N-803 + Durvalumab + PD-L1 t-haNK
Clinical trial
A Phase 1 Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2024-09-01
Clinical trial
A Phase 1, Multicenter, Dose Escalation and Dose Expansion Study to Evaluate Safety of CPO102, an Anti-claudin 18.2 Antibody-MMAE Drug Conjugate Administered Intravenously in Patients With Advanced Pancreatic and Gastric Cancers
Status: Withdrawn, Estimated PCD: 2022-11-16
Product
rhuGM-CSF
Product
CPO102
Product
APG-5918
Clinical trial
A Phase I Study of Safety, Pharmacokinetic and Efficacy of Orally Administered APG-5918 in Patients With Advanced Solid Tumors or Hematologic Malignancies
Status: Recruiting, Estimated PCD: 2024-09-30
Product
TJ033721
Clinical trial
A Safety and Efficacy Clinical Study of CEA-targeted CAR-T Therapy forCEA-positive Advanced/Metastatic Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Ulixertinib
Clinical trial
Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies
Status:
Clinical trial
A Phase II Study to Evaluate the Safety and the Efficacy of GEN-001 in Combination With Avelumab for Patients With PD-L1 Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
A Study of RC48-ADC Combine With Toripalimab and Chemotherapy or RC48-ADC Combine With Toripalimab and Herceptin as First-line Treatment in Local Advanced or Metastatic Gastric Cancer With the HER2 Expression
Status: Recruiting, Estimated PCD: 2024-07-10
Clinical trial
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2023-07-01
Product
CUE-102
Product
Herceptin
Product
KVA12123 Plus Pembrolizumab
Product
Systemic Treatment
Clinical trial
The Registry of Oncology Outcomes Associated With Testing and Treatment (ROOT)
Status: Recruiting, Estimated PCD: 2029-10-01
Clinical trial
A Phase 1, Open-Label, Dose Escalation and Expansion Study of CUE-102 Monotherapy in HLA-A*0201 Positive Patients With WT1 Positive Recurrent/Metastatic Cancers
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Trans-arterial tirapazamine embolization
Clinical trial
Phase IIA Single-Arm Study of Treatment of Patients With Advanced Liver Cancer With a Combination of TATE (Transarterial Tirapazamine Embolization) Followed by an Anti-PD-1 Monoclonal Antibody
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Multicentric Phase 1/2 Trial to Evaluate the Safety and Efficacy of SOT102 as Monotherapy and in Combination With Standard of Care Treatment in Patients With Gastric and Pancreatic Adenocarcinoma
Status: , Estimated PCD: 2023-12-01
Product
SOT102
Clinical trial
A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2020-05-27
Clinical trial
A Phase 1b/2a Two-Part, Open-Label, Multicenter Study to Evaluate the Safety and Pharmacokinetics of OC-001 as Monotherapy and in Combination With an Anti-PD-1/Anti-PD-L1 Antibody in Patients With Selected Locally Advanced or Metastatic Cancers
Status: Recruiting, Estimated PCD: 2026-03-31
Product
OC-001
Clinical trial
A Phase 1a/1b, Open-Label, Multi-Center, Dose Escalation and Expansion Study of HFB200603 (Anti-BTLA Antibody) as a Single Agent and in Combination With Tislelizumab (Anti-PD-1 Antibody) in Adult Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-12-01
Product
HFB200603
Clinical trial
A Phase I, Open-Label, Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Infused SNB-101(as SN-38) in Patients With Advanced Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Product
SNB-101
Clinical trial
A Clinical Study to Evaluate the Safety and Efficacy of Recombinant Human nsIL12 Oncolytic Adenovirus Injection (BioTTT001) in Combination With SOX and Toripalimab in Patients With Peritoneal Metastases From Gastric Cancer
Status: Not yet recruiting, Estimated PCD: 2027-11-30
Product
BioTTT001
Clinical trial
A Multi-Center, Multi-Cohort Study of the Efficacy and Safety of Anlotinib, TQB2450, and Albumin-bound Paclitaxel in CLDN18.2-regimen-failed Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Status: Not yet recruiting, Estimated PCD: 2025-08-25
Drug
Anlotinib
Drug
TQB2450
Clinical trial
TremelImumab aNd Durvalumab Combination For the Non-operatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-arm, Multi-cohort, Phase II INFINITY Study.
Status: Recruiting, Estimated PCD: 2025-04-30
Drug
AN0025
Product
Tremelimumab
Clinical trial
A Phase 1 Dose Escalation and Expanded Cohort Study of P-MUC1C-ALLO1 in Adult Subjects With Advanced or Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2026-04-01
Product
P-MUC1C-ALLO1 CAR-T cells
Product
Rimiducid
Clinical trial
Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer
Status: Active (not recruiting), Estimated PCD: 2024-12-31
Drug
Tiragolumab
Clinical trial
Using Single-cell Sequencing to Explore Tumor Microenvironment in Gastric Cancer Patients Treated With Combined Immunotherapy and Chemotherapy
Status: Recruiting, Estimated PCD: 2024-06-30
Product
SOX plus PD-1 inhibitor
Clinical trial
Duration of Postoperative Adjuvant Chemotherapy (3-4 Months Versus 5-6 Months) for Gastric Cancer Patients at Pathological N3 Stage: a Retrospective Study
Status: Recruiting, Estimated PCD: 2024-03-28
Product
Oxaliplatin and Capecitabine + S-1
Drug
toripalimab
Clinical trial
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung, and Other KK-LC-1 Positive Cancers
Status: Recruiting, Estimated PCD: 2025-09-01
Product
KK-LC-1 TCR-T cells
Clinical trial
Novel Colon Cancer Markers in Gastrointestinal Tissue and Biofluids
Status: Recruiting, Estimated PCD: 2030-10-01
Product
Protein Analysis
Product
Proteomic Profiling
Clinical trial
A Phase II Clinical Study of Adebrelimab Injection in Combination With Apatinib and Paclitaxel for Injection (Albumin-bound) as Second-line Therapy in Patients With Advanced Gastric Cancer Who Had Previously Received Immunotherapy.
Status: Not yet recruiting, Estimated PCD: 2024-12-30
Product
Adebrelimab + Apatinib + Paclitaxel
Clinical trial
Phase II Trial of Sequential Systemic Therapy Plus Intraperitoneal Paclitaxel in Gastric/GEJ Cancer Peritoneal Carcinomatosis (STOPGAP)
Status: Recruiting, Estimated PCD: 2024-12-01
Drug
FOLFOXIRI
Drug
fluorouracil
Clinical trial
INtegratioN of Trastuzumab, With or Without Pertuzumab, Into periOperatiVe chemotherApy of HER-2 posiTIve stOmach caNcer: the INNOVATION-TRIAL
Status: Active (not recruiting), Estimated PCD: 2022-12-22
Drug
Cisplatin
Product
5-fluorouracil or Capecitabine
Drug
Trastuzumab
Product
Pertuzumab
Clinical trial
Three Drugs in Advanced Gastric Cancer Neoadjuvant Chemotherapy for Stage Ⅲ Multicenter, Open, Randomized, Controlled Clinical Study
Status: Completed, Estimated PCD: 2021-12-01
Product
docetaxel,0xaliplatin,capecitabine
Product
oxaliplatin,capecitabine
Clinical trial
PD-1 Antibody(Tislelizumab) Plus Irinotecan Combined With POF in Treatment Naive Advanced Gastric Cancer: A Phase II Study.
Status: Not yet recruiting, Estimated PCD: 2024-04-11
Drug
mFOLFOX6
Product
Levo-Leucovorin
Clinical trial
Association Between ABO Polymorphism and Gastric/Colorectal Cancers
Status: Not yet recruiting, Estimated PCD: 2025-12-01
Product
quantitative Real-time PCR
Clinical trial
Retrospective Evaluation of Nivolumab in First-Line Unresectable Advanced or Metastatic Gastric Cancer (GC) and Gastroesophageal Junction Cancer (GEJC): A Non-interventional Observational Study in China
Status: Active (not recruiting), Estimated PCD: 2025-04-28
Clinical trial
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2019-02-28
Product
FPA144
Clinical trial
A Phase II Trial of Perioperative Chemotherapy With Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Efficacy and Safety of Neoadjuvant Cadonilimab and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer : a Prospective, Open-label, Single-Arm Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Drug
Cadonilimab
Clinical trial
A Multicenter, Prospective Phase II Clinical Study of Tislelizumab in Combination With Chemotherapy for the Perioperative Treatment of Resectable Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Status: Not yet recruiting, Estimated PCD: 2026-03-31
Product
SOX/XELOX
Clinical trial
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors
Status: Recruiting, Estimated PCD: 2024-12-30
Product
CAdVEC
Clinical trial
A Phase II Study of Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab Refractory Advanced Esophagogastric Cancer
Status: Completed, Estimated PCD: 2023-02-20
Product
Afatinib and Paclitaxel
Clinical trial
A Randomised Phase II Study of Zimberelimab Anti-PD1 immunOtherapy +/- Domvanalimab Anti-TIGIT Immunotherapy in Resectable Mismatch Repair Deficient Gastric and Gastro-oesophageal Junctional AdenoCarcinoma
Status: Not yet recruiting, Estimated PCD: 2026-09-01
Product
Zimberelimab + Domvanalimab
Clinical trial
Human HER2-targeted Chimeric Antigen Receptor Macrophages Therapy for HER2-positive Advanced Gastric Cancer With Peritoneal Metastases: an Exploratory Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2025-03-01
Clinical trial
XELOX Combined With Anlotinib and Penpulimab vs XELOX as Adjuvant Therapy in ctDNA Positive Gastric and Esophagogastric Junction Adenocarcinoma, a Randomized, Controlled, Multicenter Clinical Trial
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Anlotinib
Product
human HER2-targeted CAR-M cells
Clinical trial
Multicentric Randomized Study of H. Pylori Eradication and Pepsinogen Testing for Prevention of Gastric Cancer Mortality
Status: Recruiting, Estimated PCD: 2033-12-01
Product
Triple Therapy
Clinical trial
A Randomized, Multicenter Clinical Trial Comparing the Combination of Perioperative FLOT Chemotherapy and Preoperative Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Plus Gastrectomy to Perioperative FLOT Chemotherapy and Gastrectomy Alone in Patients With Advanced Gastric Cancer at High Risk of Peritoneal Recurrence
Status: Recruiting, Estimated PCD: 2026-01-01
Product
FLOT + HIPEC + Surgery
Product
FLOT
Clinical trial
Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2028-10-01
Product
PD-1/PD-L1 Inhibitors
Product
Penpulimab
Drug
XELOX
Clinical trial
Phase II Study of Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx)(HER2 Negative ARM) or Pembrolizumab + Trastuzumab+ Capecitabine／Cisplatin (HER2 Positive ARM) in Metastatic GC as First-line Treatment
Status: Active (not recruiting), Estimated PCD: 2024-02-06
Clinical trial
A Phase 1 Trial Combining WEE1 Inhibitor Adavosertib (AZD1775) With Radiation Therapy for Metastatic or Inoperable and Ineligible for Definitive Chemoradiation Esophageal and Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2024-10-31
Drug
Adavosertib
Clinical trial
Comparison of Submucosal and Subserosal Approaches Toward Optimized Indocyanine Green Tracer-Guided Laparoscopic Lymphadenectomy for Patients With Gastric Cancer: The FUGES-019 Randomized Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2020-11-27
Product
Indocyanine green
Product
Indocyanine Green
Clinical trial
A Phase II Trial of Neoadjuvant Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) With Chemoradiation (Carboplatin and Taxol) as First Line Treatment for Patients With Local Regional Advanced Gastric Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Product
Dexamethasone
Product
Diphenhydramine
Product
Famotidine
Drug
Palonosetron
Clinical trial
A Phase II Study Of Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Overexpressing Gastroesophageal Cancers
Status: Recruiting, Estimated PCD: 2028-04-01
Product
Neratinib
Clinical trial
The Impact of Multimodal Rehabilitation on the Outcomes of Gastric Adenocarcinoma Patients Following Radical D2 Gastrectomy: A Phase II, Multicenter, Open Label, and Randomized Clinical Study
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Clinical trial
Phase 1b/2 Clinical Trial of Neoadjuvant Pembrolizumab Plus Concurrent Chemoradiotherapy With Weekly Carboplatin and Paclitaxel in Adult Patients With Resectable, Locally Advanced Adenocarcinoma of the Gastroesophageal Junction or Gastric Cardia
Status: Completed, Estimated PCD: 2021-07-01
Clinical trial
Recurrent Brain Metastasis Immune Effects and RespOnse to Laser Interstitial ThermotHerapy (LITT) and Pembrolizumab in Combination (TORCH)
Status: Terminated, Estimated PCD: 2023-12-01
Product
LITT + Pembrolizumab
Clinical trial
An Open Label Phase II Study of the Efficacy and Tolerability of PRL3-ZUMAB and Predictive Biomarkers in Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2025-12-31
Product
PRL3-zumab
Clinical trial
Nab-paclitaxel Combined With Cadonilimab (AK104) for the Second-line Treatment of Advanced Gastric Cancer: A Prospective, Multicenter, Single-arm, Phase II Study
Status: Not yet recruiting, Estimated PCD: 2027-04-30
Product
Nab-paclitaxel Combined With Cadonilimab (AK104)
Clinical trial
The Single-center Randomized Study "Comparison of Safety and Effectiveness of the First Line of Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions in Primary Gastric Cancer With Isolated Peritoneal Carcinomatosis.
Status: Recruiting, Estimated PCD: 2026-01-19
Drug
Docetaxel
Product
Calcium folinate
Product
dPIPAC
Clinical trial
Metronomic Capecitabine as Adjuvant Therapy in Stage III Gastric Cancer: a Multicentre, Open-label, Parallel-group, Randomised, Controlled, Phase 3 Trial
Status: Recruiting, Estimated PCD: 2029-03-10
Product
Metronomic capecitabine
Clinical trial
A Single-arm, Open-label, Multicenter Phase II Clinical Study of Fruquintinib Combined With Sintilimab and XELOX in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Not yet recruiting, Estimated PCD: 2026-10-01
Product
Fruquintinib
Clinical trial
A Single Arm, Phase 2 Clinical Study Evaluating the Efficacy and Safety of Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Not yet recruiting, Estimated PCD: 2026-12-31
Product
SOX therapy
Clinical trial
Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal Microecology
Status: Recruiting, Estimated PCD: 2023-12-02
Product
Esomeprazole
Product
Amoxicillin
Product
Bismuth
Product
Clarithromycin
Product
5-Fluorouracil + Leucovorin
Clinical trial
A Phase I Trial of Epirubicin, Carboplatin and Capecitabine in Adult Cancer Patients
Status: Completed, Estimated PCD: 2010-01-01
Drug
UTD1
Drug
carboplatin
Clinical trial
A Single-arm, Multicenter, Open-label Phase II Study of Fruquintinib Plus SOX as a Neoadjuvant Therapy for Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-11-05
Product
Fruquintinib + SOX
Clinical trial
Effect of Helicobacter Pylori Eradication on Gastric Cancer Prevention in Korea: a Randomized Controlled Clinical Trial
Status: Active (not recruiting), Estimated PCD: 2029-12-01
Product
10-day bismuth-based quadruple therapy
Clinical trial
Reversal of Preneoplastic Metaplasia in the Stomach With MEK Inhibitor Treatment
Status: Active (not recruiting), Estimated PCD: 2024-05-01
Product
Trametinib
Clinical trial
Efficacy and Safety of Disitamab Vedotin Combined With PD-1 in Posterior Line Therapy of Advanced HER2-low Expressing Gastric Cancer
Status: Recruiting, Estimated PCD: 2025-08-01
Drug
PD-1 antibody
Clinical trial
Efficacy and Safety of Sintilimab Combined With Nab-paclitaxel and Tegio (aTS) as First-line Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Adenocarcinoma of Gastric and Gastroesophageal Junction (CZTU-1)：a Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2026-08-02
Clinical trial
Helicobacter Pylori Eradication to Prevent Gastric Cancer in Subjects With Family History of Gastric Cancer: A Randomized Controlled Study
Status: Active (not recruiting), Estimated PCD: 2018-12-01
Product
LAC Triple Therapy
Product
Epirubicin
Product
Microarray Analysis
Product
Polymorphism Analysis
Clinical trial
Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections
Status: Withdrawn, Estimated PCD: 2022-11-30
Product
Cook Medical EMR
Clinical trial
Tislelizumab Plus CapeOX ± Lenvatinib as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscore: A Multi-center, Prospective, Phase II Study
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Lenvatinib + Tislelizumab + CapeOX chemotherapy
Product
Tislelizumab + CapeOX chemotherapy
Clinical trial
PD-1 Antibody Sintilimab Combined With Modified FLOT Regimen in the Treatment of Metastatic Gastric Cancer: a Phase II Clinical Study
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for Advanced Gastric Cancer Patients With Para-aortic Lymph Node Metastasis: a Single-arm, Phase II, Exploratory Study.
Status: Recruiting, Estimated PCD: 2025-12-31
Drug
S-1
Clinical trial
Phase 2 Study of Novel SEQUEnced Immunotherapy (Pembrolizumab) With Anti-angiogenesis and Chemotherapy in Advanced Gastric and gastroesophageaL Junction (GEJ) Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-06-11
Clinical trial
Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2026-12-01
Product
XELOX + Sintilimab
Product
Standard XELOX + Sintilimab
Clinical trial
A Real-world Study to Explore and Evaluate Individualized Targeted Agents for Patients of Digestive Cancers Based on Molecular Characteristics After Standard Therapy Failure in China
Status: Recruiting, Estimated PCD: 2024-02-01
Product
FGFR Inhibitor
Product
Other Therapy
Clinical trial
Effect of Low-dose Aspirin for Stomach Cancer Prevention After Endoscopic Resection of Gastric Neoplasm (EASTERN): a Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2027-12-31
Product
Aspirin
Clinical trial
A Phase II Study of agenT-797 (Invariant Natural Killer T Cells), Botensilimab, a Novel Fc-enhanced CTLA-4 Inhibitor, Plus Balstilimab (Anti-PD-1) With Ramucirumab and Paclitaxel for Patients With Previously Treated, Advanced Esophageal, Gastric, or Gastro-esophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2027-08-01
Product
AgenT-797
Clinical trial
Study of Induction SBRT and Olaparib Followed by Combination Pembrolizumab/Olaparib in Gastric and Gastroesophageal Junction (GEJ) Cancers
Status: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
Status: Active (not recruiting), Estimated PCD: 2024-07-01
Product
Crizotinib
Drug
Botensilimab
Product
Balstilimab
Clinical trial
Multicentric Transnational H. Pylori Screen-and-treat Study in a Population of Young Adults
Status: Recruiting, Estimated PCD: 2026-10-01
Product
Bismuth-based quadruple therapy
Product
Levofloxacin-based quadruple therapy
Product
Standard Triple Therapy
Product
Levofloxacin-based triple
Clinical trial
ONO-4538 Phase III Study A Multicenter, Double-Blind, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer
Status: Completed, Estimated PCD: 2016-08-01
Product
ONO-4538
Clinical trial
TAS-102 Combined With Anlotinib in Patients With Metastatic Gastric Cancer Refractory to Standard Treatments (THALIA): a Prospective Single-arm Phase II Study
Status: Recruiting, Estimated PCD: 2024-12-31
Drug
TAS 102
Clinical trial
Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft für Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI)
Status: Active (not recruiting), Estimated PCD: 2026-02-01
Drug
5-FU
Product
sodium folinate
Clinical trial
Quantification of 68-GaNOTA-Anti-HER2 VHH1 Uptake in Metastasis of Breast Carcinoma Patients and Assessment of Repeatability (VUBAR) - Pilot Study
Status: Recruiting, Estimated PCD: 2024-11-01
Product
68GaNOTA-Anti-HER2
Clinical trial
Comparison of SEEOX and SOX Chemotherapeutic Regimens in Stage ⅢB/ⅢC Gastric Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2019-05-21
Drug
oxaliplatin
Drug
etoposide
Product
pharmorubicin
Clinical trial
A Prospective Randomized Controlled Study of the Efficacy of Carbon Nanoparticles Versus Indocyanine Green in Robotic or Laparoscopic Gastrectomy
Status: Active (not recruiting), Estimated PCD: 2023-03-09
Product
Carbon nanoparticles
Clinical trial
Phase IB Trial of Induction Nivolumab or Nivolumab/Relatlimab Prior to Concurrent Chemoradiation in Patients With Operable Stage II/III Esophageal/ Gastroesophageal Junction Cancer
Status: Active (not recruiting), Estimated PCD: 2024-09-01
Clinical trial
Phase I Trial of CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Status: Recruiting, Estimated PCD: 2026-09-30
Product
CA-4948
Clinical trial
Neoadjuvant of Sintilimab Combined Weekly Metronomic Chemotherapy (PLOF) for Resectable Locally Advanced Gastric Cancer : A Phase Il Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
mFOLFOX7
Clinical trial
A Multicentre Randomised Phase II Trial of Neo-adjuvant Chemotherapy Followed by Surgery vs. Neo-adjuvant Chemotherapy and Subsequent Chemoradiotherapy Followed by Surgery vs. Neo-adjuvant Chemoradiotherapy Followed by Surgery in Resectable Gastric Cancer
Status: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
Prospective, Single Center, Phase II Study of Disitamab Vedotin（RC48) Combined With Sintilimab Plus XELOX for Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression
Status: Not yet recruiting, Estimated PCD: 2024-12-31
Product
RC48 + Sintilimab + XELOX
Clinical trial
A Phase II Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Homologous Recombination (HR) Defective or Loss of Heterozygosity (LOH) High Metastatic Esophageal/Gastroesophageal Junction/Proximal Gastric Adenocarcinoma
Status: Terminated, Estimated PCD: 2022-11-17
Product
Niraparib
Clinical trial
The Efficacy of Pressurised Intraperitoneal Aerosol Chemotherapy (PIPAC) Combined With CURativE Intent Minimally Invasive Radical Resection in High-risk Gastric Cancer Patients. A Multicentre, Randomised, Open-label Phase-II Study
Status: Not yet recruiting, Estimated PCD: 2027-01-01
Product
Doxorubicin
Clinical trial
XELOX for 4 Months Versus 6 Months as Adjuvant Chemotherapy in Gastric Cancer After D2 Resection (LOMAC)
Status: Active (not recruiting), Estimated PCD: 2026-08-01
Clinical trial
Phase II Clinical Study of Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer
Status: Recruiting, Estimated PCD: 2026-10-10
Product
Adebrelimab，Fruquintinib
Clinical trial
Targeted Chemoprevention of Gastric Carcinogenesis in High Risk Populations
Status: Active (not recruiting), Estimated PCD: 2022-12-20
Product
Eflornithine
Clinical trial
A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
KD-496
Clinical trial
Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Single Center, Open Label Trial, Phase 2/3
Status: Recruiting, Estimated PCD: 2027-12-01
Clinical trial
Neoadjuvant Systemic and Peritoneal Chemotherapy for Regionally Advanced Gastric Cancer With Minimal Peritoneal Disease
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Doxorubicin + Cisplatin
Clinical trial
A Phase I/II Study of Trifluridine/Tipiracil (TAS102) in Combination With Nanoliposomal Irinotecan (NAL-IRI) in Advanced GI Cancers
Status: Recruiting, Estimated PCD: 2024-11-28
Drug
Liposomal Irinotecan
Product
Trifluridine and Tipiracil Hydrochloride
Clinical trial
Phase II Clinical Study of Fruquintinib Combined TAS102 for Second-line Treatment of Advanced Gastric Cancer
Status: Recruiting, Estimated PCD: 2026-10-10
Clinical trial
Two-Part, Phase Ib/II, Open Label, Single-Arm, Multi-center Study to Evaluate the Safety and Efficacy of Varlitinib in Combination With Weekly Paclitaxel in EGFR/HER2 Co-expressing Advanced or Metastatic Gastric Cancer Patients
Status: Completed, Estimated PCD: 2021-12-13
Product
Variltinib
Clinical trial
Evaluation of the Efficacy and Safety of Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant and Conversion Therapy for Advanced Gastric Cancer (RNPLS-01)
Status: Recruiting, Estimated PCD: 2025-12-31
Product
nab-paclitaxel
Clinical trial
Concomitant Intraperitoneal and Systemic Chemotherapy in Patients With Extensive Peritoneal Carcinomatosis of Gastric Origin
Status: Recruiting, Estimated PCD: 2024-08-01
Drug
Irinotecan
Drug
CAPOX
Clinical trial
A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2022-01-19
Clinical trial
Adjuvant Treatment in Cancer Patients With Neoantigen-primed DC Vaccine : a Single-arm, Open-label, Prospective Clinical Trial
Status: Recruiting, Estimated PCD: 2025-12-31
Product
DC vaccine
Clinical trial
A Radio-Pathomic Multimodal Machine Learning Model for Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer: A Retrospective Observational Study
Status: Recruiting, Estimated PCD: 2022-09-30
Product
Neoadjuvant chemotherapy
Clinical trial
A Randomized Controlled Study of 2nd-line Treatment of Advanced G/GEJ Adenocarcinoma With Fruquintinib and Albumin-paclitaxel in Combination With or Without PD-1 Antibody in Patients Who Have Failed Treatment With PD-1 Antibody
Status: Not yet recruiting, Estimated PCD: 2026-05-31
Product
PD-1inhibitor
Clinical trial
A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage Lymphoma Proto-oncogene (CBL-B) Inhibitor, in Adults With Advanced Malignancies, With Phase 1b Expansion in Select Tumor Types
Status: Recruiting, Estimated PCD: 2024-08-31
Product
NX-1607
Clinical trial
A Phase Ib Adaptive Study Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without Bevacizumab
Status: Active (not recruiting), Estimated PCD: 2023-06-22
Drug
Atezolizumab
Product
Dasatinib
Clinical trial
A Phase 1b/2a Study to Assess the Safety, Tolerability, PK, and Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Patients With Metastatic Colorectal or Gastric Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-05-31
Product
TEW-7197
Clinical trial
A Phase Ib/II, Multicenter, Open-Label Study of TT-00420 Tablet, as Monotherapy or in Combination Regimens, in Patients With Advanced Solid Tumors
Status: Completed, Estimated PCD: 2024-02-20
Drug
Nab-Paclitaxel
Clinical trial
Phase I Clinical Trial Testing the Dose Escalation and Expansion of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration for the Management of Pleural Carcinosis
Status: Recruiting, Estimated PCD: 2025-12-01
Product
Cisplatine Teva
Clinical trial
Exploratory Study of Gastric Cancer Organoids in the Screening of Neoadjuvant Chemotherapy and Immunotherapy Drugs
Status: Recruiting, Estimated PCD: 2024-06-28
Clinical trial
Phase II Clinical Study of Adebrelimab and Fruquintinib Combined With Paclitaxel/Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer After First-line Treatment With PD-1 Antibody Failed
Status: Recruiting, Estimated PCD: 2026-10-10
Clinical trial
A Multi-Center Phase I Trial of Neratinib and Fam-trastuzumab Deruxtecan in Advanced Refractory Gastric and Esophageal Cancer Patients
Status: Recruiting, Estimated PCD: 2025-06-01
Product
Fam-Trastuzumab Deruxtecan-Nxki
Clinical trial
A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patients With Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas Treated by a Combination of Immune Checkpoint Inhibitors (Botensilimab + Balstilimab) Versus the Standard of Care (FOLFOX/XELOX + Nivolumab)
Status: Not yet recruiting, Estimated PCD: 2028-05-15
Product
Folfox
Drug
T-VEC
Clinical trial
Envollizumab Combined With Fruquintinib and SOX Versus SOX for Conversion Therapy in Her-2 Negative Unresectable Locally Advanced Gastric Cancer: a National Multicenter Randomized Controlled Study
Status: Not yet recruiting, Estimated PCD: 2025-07-30
Product
Envolimab
Product
Tegafur
Clinical trial
Nivolumab and CAPOX in Patients With FGFR2/PD-L1-positive Metastatic Gastric Adenocarcinoma: a Single-arm, Phase 2 Study
Status: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Recruiting, Estimated PCD: 2027-12-01
Drug
cyclophosphamide
Drug
fludarabine
Drug
interleukin-2
Clinical trial
Autologous T Cells Modified by Chimeric Antigen Receptor Targeting EpCAM for Clinical Research on Advanced Digestive System Malignancies
Status: Recruiting, Estimated PCD: 2024-12-30
Product
EPCAM CAR-T
Product
anti-KRAS G12D mTCR PBL
Clinical trial
Clinical Outcomes of Indocyanine Green Tracer Using in Laparoscopic Gastrectomy With Lymph Node Dissection for Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy
Status: Active (not recruiting), Estimated PCD: 2026-10-01
Clinical trial
Dose Exploration of Ciprofol for Sedation in Gastrointestinal Endoscopic Diagnosis and Treatment of Obese Patients.
Status: Recruiting, Estimated PCD: 2022-11-03
Product
ciprofol
Clinical trial
The Effect of Prucalopride Succinate on Gastrointestinal Motility After Laparoscopic Gastrectomy : Prospective Double Blind Case-control Study
Status: Completed, Estimated PCD: 2023-06-30
Product
Prucalopride
Product
Mosapride citrate
Clinical trial
Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients
Status: Active (not recruiting), Estimated PCD: 2023-12-01
Clinical trial
A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2025-03-01
Product
IPH5301
Clinical trial
A Multicenter Phase II Non-randomised Trial Assessing the Efficacy of DKN-01 Plus Atezolizumab in Patients With Advanced Mismatch Repair Proficient Oesophagogastric Cancer
Status: Recruiting, Estimated PCD: 2024-05-30
Clinical trial
Pilot Evaluation of Focused Ultrasound Ablation and Focused Ultrasound Ablation Plus PD-1 Antibody Blockade in Advanced Solid Tumors
Status: Active (not recruiting), Estimated PCD: 2024-02-01
Product
Poly ICLC
Clinical trial
Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer
Status: Active (not recruiting), Estimated PCD: 2021-12-01
Drug
bevacizumab
Product
trastuzumab
Drug
mFOLFIRINOX
Clinical trial
A Phase I/II Study Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Status: Recruiting, Estimated PCD: 2027-06-29
Product
Anti-KRAS G12V mTCR PBL
Clinical trial
Preventive HIPEC in Combination With Perioperative FLOT Versus FLOT Alone for Resectable Diffuse Type Gastric and Gastroesophageal Junction Type II/III Adenocarcinoma - The Phase III "PREVENT" Trial of the AIO /CAOGI /ACO
Status: Recruiting, Estimated PCD: 2026-11-01
Clinical trial
Postgenome-based Systemic Discovery of Strong Biomarkers Predict Gastric Cancer Chemotherapy Response
Status: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Comparison Between Epinephrine Versus Tranexamic Acid Usage During Upper Gastrointestinal Tract Endoscopic Resection Procedures for the Reduction of Intraprocedural and Postprocedural Bleeding
Status: Recruiting, Estimated PCD: 2025-02-01
Product
Tranexamic acid
Product
Epinephrine
Product
Standard of Care PD-1 Therapy
Clinical trial
Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer(KCSG ST14-05)
Status: Recruiting, Estimated PCD: 2026-08-01
Clinical trial
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
Status: Recruiting, Estimated PCD: 2027-02-02
Product
LVGN3616
Product
LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
Clinical trial
Phase II Study of Neoadjuvant Immunotherapy Plus Chemotherapy in Borrmann Type 4 and Large Type 3 Gastric Cancer (Neo-ICEBOAT Study)
Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
Perioperative FLOT Versus Adjuvant XELOX for Locally Advanced Gastric Cancer - a Randomized Controlled Study
Status: Recruiting, Estimated PCD: 2024-12-31
Product
5-FU, Leucovorin, Oxaliplatin, Docetaxel
Clinical trial
Diagnostic Value of Intraoperative Near-infrared Imaging With Indocyanine Green for Detection of Peritoneal Metastases During Staging Laparoscopy for Gastric Adenocarcinoma: a Prospective, Multicentric Study.
Status: Terminated, Estimated PCD: 2024-03-27
Product
LVGN3616 + LVGN6051 + LVGN7409 + Bevacizumab + Cyclophosphamide
Clinical trial
A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours
Status: Recruiting, Estimated PCD: 2026-08-19
Product
Datopotamab deruxtecan
Drug
Saruparib
Clinical trial
Pilot Study of Dual Checkpoint Inhibition Followed by Immuno-Chemoradiation in Patients With Resectable Gastric Adenocarcinoma (Concept ID 2016-NIV-0551)
Status: Active (not recruiting), Estimated PCD: 2026-12-30
Drug
Lurbinectedin
Product
Prednisone
Clinical trial
A Phase II Study of Neoadjuvant Transcatheter Arterial Chemoembolization（TACE）Plus PD-1 Antibody (Tislelizumab) in the Locally Advanced Stomach Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Transcatheter Arterial Chemoembolization
Clinical trial
Single Arm Clinical Prospective Study of Neoantigen Reactive T Cells (NRTs) in the Treatment of Chinese Patients With Advanced Gastric Cancer
Status: Not yet recruiting, Estimated PCD: 2026-01-01
Product
Neoantigen Reactive T Cells
Clinical trial
A Phase II Study of Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis
Status: Active (not recruiting), Estimated PCD: 2023-02-25
Clinical trial
Cadonilimab Plus CapeOX as First-Line Treatment for Advanced GC/GEJC With High Tumor Microenvironment Score (TMEscore).
Status: Not yet recruiting, Estimated PCD: 2026-04-01
Product
Cadonilimab plus CapeOX chemotherapy
Clinical trial
A Phase 1a/1b Study of BG-68501, a Selective CDK2 Inhibitor, in Participants With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-12-31
Product
BG-68501
Drug
Alpelisib
Clinical trial
A Phase II Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies
Status: Completed, Estimated PCD: 2023-03-10
Clinical trial
The Incidences Of Hypoxia And Severe Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol Compared With Propofol In Overweight Or Obesity Adults Patients, A Multicenter, Randomized, Controlled Trial
Status: Completed, Estimated PCD: 2023-08-15
Product
Ciprofol
Clinical trial
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB598 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
Status: Recruiting, Estimated PCD: 2025-08-01
Product
AB598
Clinical trial
A Single-Center, Prospective Phase II Clinical Study of Liposomal Irinotecan Monotherapy for Third-Line and Beyond Recurrent/Refractory Advanced Gastric Cancer
Status: Not yet recruiting, Estimated PCD: 2025-02-28
Product
Liposomal Irinotecan
Clinical trial
Clinical Application of Efficacy Prediction Model Based on Epigenetics Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Terelizumab
Drug
CapeOx
Clinical trial
A Phase II Study Evaluating Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma
Status: Active (not recruiting), Estimated PCD: 2024-02-14
Product
Telatinib
Drug
pembrolizumab
Clinical trial
The Efficacy and Safety of Chemotherapy Combined With Cadonilimab (AK104) in Neoadjuvant Treatment of Locally Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma: A Prospective, Single-arm, Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2025-01-01
Product
Propofol
Clinical trial
Intraperitoneal Aerosolized Nanoliposomal Irinotecan (Nal-IRI) in Peritoneal Carcinomatosis From Gastrointestinal Cancer: a Phase I Study
Status: Recruiting, Estimated PCD: 2025-08-01
Product
PIPAC with Nal-IRI
Clinical trial
A Phase IIa Study of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and PD-L1 Expression in Gastric Cancer With Peritoneal Metastases
Status: Recruiting, Estimated PCD: 2024-06-01
Product
Mitomycin
Clinical trial
Clinical Research of High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Vitamin C
Drug
Metformin
Clinical trial
A Randomized Phase II Study Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2022-03-15
Clinical trial
Safety and Efficacy of Preoperative Adjuvant SOX Regimen Combined With PD-1 Antibody Versus FLOT Regimen With PD-1 Antibody for the Treatment of Localized Deficient Mismatch Repair Gastric Cancer: a Chinese Trial
Status: Recruiting, Estimated PCD: 2025-01-01
Product
SOX+PD-1 antibody
Product
FLOT+PD-1 antibody
Clinical trial
Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients, a Multi-center, Prospective, Single-arm Phase II Trial
Status: Recruiting, Estimated PCD: 2026-07-01
Product
Lenvatinib + Sintilimab
Clinical trial
A Phase II Study of Perioperative mFOLFOX (Fluorouracil, Leucovorin, and Oxaliplatin) Chemotherapy Plus Pembrolizumab(MK-3475) Combination in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach (MISP #52216)
Status: Active (not recruiting), Estimated PCD: 2024-04-30
Product
Neoadjuvant Treatment - mFOLFOX6 & Pembrolizumab
Product
mFOLFOX & Pembrolizumab
Clinical trial
Infusional Fluorouracil and Weekly Docetaxel as First-line Therapy for Gastric Cancer With Bone Marrow Metastasis and Disseminated Intravascular Coagulation: a Multi-center, Phase II Trail
Status: Completed, Estimated PCD: 2024-02-25
Clinical trial
Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus
Status: Completed, Estimated PCD: 2009-09-01
Product
cisplatin
Drug
paclitaxel
Clinical trial
A Phase I and Randomized Phase II Double Blinded Placebo Controlled Study of mFOLFOX6 +/- AMG 337 in the First Line Treatment of Patients With Her2/Neu Negative and High MET Expressing Advanced Gastric and Esophageal Adenocarcinoma
Status: , Estimated PCD: 2015-03-06
Product
AMG 337
Clinical trial
Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer: an Multicenter, Open, Randomized, Controlled Clinical Study
Status: Active (not recruiting), Estimated PCD: 2022-07-22
Drug
Abraxane
Drug
S1
Clinical trial
ONO-4538 Phase II/III Study A Multicenter, Randomized Study in Patients With Unresectable Advanced or Recurrent Gastric Cancer
Status: Completed, Estimated PCD: 2020-01-01
Clinical trial
Surgical Conversion of Candonilimab (AK104) Combined With Paclitaxel, S-1 and Apatinib for Unresectable Advanced Gastric(G)/Gastroesophageal Junction(GEJ) Cancer
Status: Recruiting, Estimated PCD: 2025-03-21
Clinical trial
Prospective, Single Arm, Single Center Exploratory Study on the New Adjuvant Therapy of Camrelizumab Combined With XELOX Regimen for Locally Advanced Gastric Cancer
Status: Recruiting, Estimated PCD: 2024-03-01
Product
Carrelizumab
Clinical trial
A Randomized, Open-label Phase II/III Efficacy and Safety Study of Atezolizumab in Combination With FLOT Versus FLOT Alone in Patients With Gastric Cancer and Adenocarcinoma of the Oesophago-gastric Junction and High Immune Responsiveness (MO30039/MO43340) - The DANTE Trial
Status: Recruiting, Estimated PCD: 2027-05-31
Clinical trial
A Genotype-Guided Dosing Study of FOLFIRABRAX in Previously Untreated Patients With Advanced Gastrointestinal Malignancies
Status: Completed, Estimated PCD: 2017-12-01
Product
Paclitaxel Albumin-Stabilized Nanoparticle
Clinical trial
The Effects of Sex and Age Differences on Gastric Cancer in Terms of Incidence of Histologic Subtypes and Survival Rate: a Retrospective Study
Status: Completed, Estimated PCD: 2021-09-01
Product
Sex, Age
Clinical trial
A Phase Ib/II Open Label, Multi-arm, Parallel Cohort Dose Finding and Expansion Study to Assess the Safety, Pharmacokinetics and Efficacy of NUC-3373, a Nucleotide Analogue, Given in Combination With Standard Approved Agents in Patients With Advanced Solid Tumours
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Fosifloxuridine
Clinical trial
Perioperative Chemotherapy Plus PD-1 Antibody Compared With Perioperative Chemotherapy in the Locally Advanced Gastric Cancer: a Open-label, Phase 2 Randomised Controlled Trial
Status: Active (not recruiting), Estimated PCD: 2022-06-27
Product
Tegafur- Gimeracil-Oteracil potassium
Drug
Varlilumab
Clinical trial
A Phase II Study of FOLFOX Combined With Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma. Big Ten Cancer Research Consortium: BTCRC-GI15-015
Status: Completed, Estimated PCD: 2022-12-27
Clinical trial
A Study of Compared Adjuvant Serplulimab and Trastuzuma and Chemotherapy vs Chemotherapy Only in Her-2 Positive Gastric Cancer With II-III Stage Following Curative Resection
Status: Recruiting, Estimated PCD: 2026-01-01
Product
Serplulimab
Product
Trastuzuma
Clinical trial
A Prospective, Non-randomized, Multicenter, Phase II Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Unresectable Recurrent or Metastatic Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Camrelizumab + Apatinib + SOX
Product
Camrelizumab + Apatinib
Clinical trial
Neo-Sequence 1: Phase 2 Study of Neoadjuvant Chemotherapy With or Without Antiangiogenesis and Sequential Immunotherapy for HER2-negative MMR-proficient Locally Advanced Gastric or Gastroesophageal Adenocarcinoma
Status: Completed, Estimated PCD: 2023-12-31
Product
SOX plus Paclitaxel with or without antiangiogenesis followed by PD-1 antibody
Clinical trial
Evaluation of Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer in Patients With Peritoneal Carcinomatosis
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Intraperitoneal chemotherapy
Clinical trial
Phase II Trial of Post-Operative Adjuvant Paclitaxel + Cisplatin in Patients With Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction or Cardia
Status: , Estimated PCD: 2003-10-01
Clinical trial
A Phase I/II Trial of Cabozantinib in Combination With Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Gastroesophageal Cancer and Other Gastrointestinal (GI) Malignancies (CAMILLA)
Status: Active (not recruiting), Estimated PCD: 2026-11-30
Product
Cabozantinib
Clinical trial
Tislelizumab in Combination With Pre-operative Chemoradiotherapy Versus SOC for Patients With Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: a Multicenter, Randomized, Open-label, Phase IIB Trial
Status: Recruiting, Estimated PCD: 2027-02-28
Drug
PD-1 monoclonal antibody
Product
Nab paclitaxel
Clinical trial
Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric Cancer, a Small-scale, Exploratory Real-world Study
Status: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma
Status: Recruiting, Estimated PCD: 2025-06-08
Clinical trial
An Open Label, Single-arm, Multicenter Phase Ib/II Study to Evaluate the Safety and Efficacy of T-Dxd in Combination With Ramucirumab as a 2nd Line in Patients With HER2 Low Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Status: Not yet recruiting, Estimated PCD: 2025-05-01
Product
T-Dxd
Clinical trial
A Phase I Clinical Study of Anti-CEA CAR-T Therapy in the Treatment of CEA-positive Advanced Malignant Solid Tumors
Status: Recruiting, Estimated PCD: 2024-05-15
Clinical trial
Clinical Study on the Safety and Efficacy of GK01 Autologous Tumor-reactive T Cells (TRT) in Patients With Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2026-07-19
Product
TCR T-cells
Clinical trial
Fecal Microbiota Transplantation Combined With SOX and Sintilimab as First-line Treatment for Advanced Gastric Cancer:A Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study (FMT-JSNO-01)
Status: Not yet recruiting, Estimated PCD: 2027-06-01
Product
Fecal Microbiota Transplantation
Clinical trial
A Single-arm, Open-label, Multicenter Phase 2 Study to Evaluate XELOX + Tislelizumab in Combination With Doxorubicin Hydrochloride Liposome Injection （XELOX+PD-1+PLD）as Neoadjuvant Therapy for Resectable Gastric Cancer
Status: Recruiting, Estimated PCD: 2023-09-30
Drug
pegylated liposomal doxorubicin
Clinical trial
Effect of Perioperative Probiotic Supplements on Postoperative Short-term Outcomes in Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy: A Prospective, Randomized, Controlled, Multicenter Clinical Trial
Status: Recruiting, Estimated PCD: 2024-03-01
Product
Live Combined Bifidobacteriun, Lactobacillus and Enterococcus Capsules
Clinical trial
A Dose-Escalation and Dose-Expansion Study Evaluating the Safety and Efficacy of Personalized Neoantigen Vaccine in Advanced Gastric Cancer, Esophageal Cancer and Liver Cancer
Status: Recruiting, Estimated PCD: 2024-12-01
Product
Neoantigen Tumor Vaccine
Clinical trial
A Phase 2, Multicenter, Single Arm, Open Label, Non-Randomized Study of [18F]FAPI-74 PET in Patients With Gastrointestinal Cancers
Status: Recruiting, Estimated PCD: 2024-07-31
Product
FAPI-74
Clinical trial
Efficacy and Safety of Fruquintinib in Combination With PD-1 Inhibitors as First-line Maintenance Therapy for Advanced HER-2 Negative Gastric Cancer: a Single-arm, Prospective, Exploratory Clinical Study
Status: Recruiting, Estimated PCD: 2025-03-01
Product
Fruquintinib+PD-1
Clinical trial
An Exploratory Study of Immunotherapy Combined With Anlotinib Hydrochloride Capsules and Chemotherapy in Perioperative Treatment of Locally Advanced Novel Coronavirus Infected Gastric Cancer
Status: Not yet recruiting, Estimated PCD: 2024-02-01
Product
Penpulimab + Anlotinib Hydrochloride Capsules + Chemotherapy; Cadonilimab + Anlotinib Hydrochloride Capsules + Chemotherapy
Clinical trial
Effect of Helicobacter Pylori Eradication After Subtotal Gastrectomy on Survival Rate of Gastric Cancer Patients: Retrospective Study
Status: Completed, Estimated PCD: 2020-01-30
Product
Helicobacter pylori eradication
Clinical trial
Efficacy and Safety of Disitamab Vedotin Combined With Sintilimab in Second-line Treatment of Advanced Gastric Cancer: a Prospective, Single Arm Clinical Study (DVES)
Status: Not yet recruiting, Estimated PCD: 2025-07-01
Product
Disitamab Vedotin + Sintilimab
Clinical trial
Phase II Trial of Pembrolizumab in Combination With Trastuzumab, Fluoropyrimidine, and Platinum Chemotherapy in First Line Stage IV HER2-positive Metastatic Esophagogastric (EG) Cancer
Status: Completed, Estimated PCD: 2022-06-01
Clinical trial
CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET
Status: Recruiting, Estimated PCD: 2024-12-31
Product
CKD-702
Clinical trial
HMBD-001 (an Anti-HER3 Monoclonal Antibody) Given Intravenously as a Single Agent and in Combination in Patients With Advanced HER3 Positive Solid Tumours
Status: Recruiting, Estimated PCD: 2026-09-01
Product
HMBD-001
Drug
capecitabine
Clinical trial
A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer: a Single-center, Open-label, Randomized Controlled Trial
Status: , Estimated PCD: 2025-01-01
Product
camrelizumab+chemotherapy
Clinical trial
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Status: Recruiting, Estimated PCD: 2025-12-01
Product
ETX-19477
Clinical trial
A Single-center, Open-label, Single-arm Clinical Study of the Safety and Efficacy of KD-496 CAR-T Therapy in Advanced NKG2DL+/CLDN18.2+ Solid Tumors
Status: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
Triplex CTLA4/PD1/PDL1 Checkpoint Inhibitors Combination Therapy for Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2024-10-30
Product
Ipilimumab + Pembrolizumab + Durvalumab
Clinical trial
The Efficacy and Safety of HIPEC Combined With PD-1 and SOX Chemotherapy for the Translational Treatment of Gastric or Esophagogastric Junctional Cancer With Peritoneal Metastasis: A Prospective, Multicenter Phase II Study
Status: Not yet recruiting, Estimated PCD: 2025-05-31
Product
HIPEC
Product
Systemic therapy
Clinical trial
Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II Study (BIG)
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Product
EXL01
Clinical trial
The Effect of Chemoradiotherapy on Gastric Perfusion in Patients With Gastric Cancer.
Status: Terminated, Estimated PCD: 2023-12-29
Clinical trial
A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori Eradication
Status: Completed, Estimated PCD: 2021-12-30
Product
Bismuth Colloidal Pectin Granules Quadruple Therapy
Clinical trial
Rescue Therapy for Helicobacter Pylori Eradication: A Randomized and Non-inferiority Trail of High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy
Status: Completed, Estimated PCD: 2021-12-20
Product
Tetracycline
Product
Furazolidone
Clinical trial
A Phase 1, Open-Label, Multicenter, Dose Escalation Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of IMM2902 in Patients With HER2-Expressing Advanced Solid Tumors
Status: Recruiting, Estimated PCD: 2023-12-01
Product
IMM2902
Clinical trial
Efficacy and Safety of Berberine Hydrochloride, Amoxicillin and Rabeprazole Triple Therapy in the First Eradication of Helicobacter Pylori
Status: Completed, Estimated PCD: 2021-12-20
Product
Berberine
Product
Rabeprazole
Clinical trial
A Multicenter, Double-blind, Randomized Study in Patients With Gastric Cancer Undergoing Postoperative Adjuvant Chemotherapy
Status: Completed, Estimated PCD: 2022-08-17
Product
Tegafur-gimeracil-oteracil potassium
Clinical trial
Phase II Trial of Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology
Status: Active (not recruiting), Estimated PCD: 2025-10-01
Product
Sodium Thiosulfate
Clinical trial
Multicenter Randomized Controlled Trial of Gastric Endoscopic Submucosal Dissection With or Without Epineprhine Added Solution
Status: Completed, Estimated PCD: 2022-12-31
Clinical trial
SOX Combined With Tislelizumab and Low-dose Radiation Therapy for Neoadjuvant Treatment of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: a Prospective, Multi-center, Single-arm, Phase Ib/II Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2026-06-30
Product
SOX+Tislelizumab+LDRT
Clinical trial
A Randomized, Multicenter, Open-label, Phase III Study to Compare the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab, Fluoropyrimidine-based and Platinum-based Chemotherapy (Hereinafter Referred to as "Chemotherapy") Versus Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Status: Active (not recruiting), Estimated PCD: 2027-02-01
Clinical trial
A Multicenter, Prospective, Phase Ⅱ Clinical Study of Nivolumab Combined With SOX in the Perioperative Treatment of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Nivolumab + SOX
Clinical trial
Sintilimab Combined With Low-dose Radiation Therapy for Neoadjuvant Treatment of Locally Advanced Deficient Mismatch Repair/Microsatellite Instability-high Gastric Cancer: a Prospective, Multi-center, Single-arm, Phase Ib/II Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2027-06-30
Product
Sintiliman plus LDRT
Clinical trial
Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II
Status: Completed, Estimated PCD: 2023-08-30
Clinical trial
Efficacy and Safety of Perioperative Chemotherapy Combined With Tislelizumab and Trastuzumab in Patients With HER2-positive Resectable Gastric or Gastr-oesophageal Junction Carcinoma (GC/EGJ) -- a Prospective, Single-arm, Phase II Study
Status: Recruiting, Estimated PCD: 2025-12-31
Product
Tirelizumab
Clinical trial
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)
Status: Active (not recruiting), Estimated PCD: 2022-10-19
Clinical trial
[68Ga]Ga-FAPI PET/CT: The Dagnostic Accuracy for Primary Staging and Re-staging After Chemotherapy in Patients With Gastric and Gastro-esophageal Junctional Cancer
Status: Recruiting, Estimated PCD: 2025-01-01
Product
68Ga-FAPi-46
Clinical trial
Safety and Efficacy of Disitamab Vedotin Combined With Sintilimab as First-line Treatment of Elderly Patients With HER2 Overexpression Gastric Cancer
Status: Not yet recruiting, Estimated PCD: 2024-03-01
Product
Disitamab Vedotin Combined With Sintilimab
Clinical trial
Exploratory Clinical Study of TCRx_T Cells in the Treatment of Advanced or Recurrent Gastric/Gastroesophageal Junction Cancer After Failure of First Chemotherapy
Status: Not yet recruiting, Estimated PCD: 2026-03-01
Product
Tcrx T
Clinical trial
Perioperative Surufatinib Plus Sintilimab Combined With Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: the Phase 2 Solids-01 Trial
Status: Not yet recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Single-Arm Pilot Study of Adjuvant Pembrolizumab Plus Trastuzumab in HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection
Status: Terminated, Estimated PCD: 2022-12-30
Clinical trial
Perioperative Immunotherapy vs. Chemo-immunotherapy Stratified by Early Response Evaluation in Patients With Advanced Gastric Cancer (GC) and Adenocarcinoma of the Esophago-gastric Junction (AEG)
Status: Active (not recruiting), Estimated PCD: 2024-03-01
Drug
relatlimab
Product
Folic acid
Clinical trial
Clinical Study of Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced Microsatellite-unstable Gastric Adenocarcinoma
Status: Recruiting, Estimated PCD: 2024-03-01
Product
pabolizumab
Clinical trial
A Phase II Trial of Neoadjuvant Paclitaxel - Cisplatin Chemotherapy, Surgery and Adjuvant Radiation Therapy and 5-FU/Leucovorin for Gastric Cancer
Status: Completed, Estimated PCD: 2010-02-01
Clinical trial
Indocyanine Green Lymphangiography as a Tool for Improving Lymphadenectomy in Gastric Cancer
Status: Withdrawn, Estimated PCD: 2022-01-01
Clinical trial
A Phase 3, Open-Label, Randomized Study to Compare Adjuvant Chemotherapy of Docetaxel/Capecitabine/Oxaliplatin Versus Capecitabine/Oxaliplatin in Advanced Gastric Cancer Patients at Stage IIIB and IV (M0) (Based on AJCC Ed. 6) Who Received Radical Resection(KCSG ST15-08)
Status: Recruiting, Estimated PCD: 2028-06-30
Product
Docetaxel + Capecitabine + Oxaliplatin
Product
Capecitabine + Oxaliplatin
Clinical trial
Phase II Clinical Study of PD1 Antibody (SHR-1210) Combined With Trastuzumab, Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction Adenocarcinoma
Status: Active (not recruiting), Estimated PCD: 2024-01-31
Clinical trial
Exploratory Clinical Trial on the Safety, Efficacy, and Pharmacokinetics of XKDCT086 (iPD-1-Claudin18.2-CAR-T) in Claudin 18.2 Positive Advanced Solid Malignant Tumors: a Single Center, Single Arm, Dose-increasing Trial
Status: Recruiting, Estimated PCD: 2025-02-28
Product
Chimeric antigen receptor T cell preparation targeting Claudin18.2
Clinical trial
Neo-Sequence 2：Phase 2 Study of Neoadjuvant Chemotherapy Plus Anti-angiogenesis Therapy and Immunotherapy for Locally Advanced Diffuse Gastric Cancer
Status: Recruiting, Estimated PCD: 2027-03-01
Product
Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy
Clinical trial
Clinical Efficacy and Safety of Adjuvant Immunotherapy (Tirelizumab) Plus Chemotherapy Versus Adjuvant Chemotherapy Alone in Lymph Node Positive Patients With Gastric Cancer After D2 Radical Resection
Status: Recruiting, Estimated PCD: 2023-06-01
Drug
tirelizumab
Product
Chemotherapy with Oxaliplatin + Heroda
Clinical trial
A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.
Status: Completed, Estimated PCD: 2023-02-06
Product
Oxaliplatin+Capecitabine+Pembrolizumab
Clinical trial
Sintilimab Combined With Fruquintinib and Chemotherapy Versus Sintilimab and Chemotherapy for Conversion Therapy in Unresectable Stage IV Gastric Cancer: a National Multicenter Randomized Controlled Study
Status: Not yet recruiting, Estimated PCD: 2026-06-01
Product
Sintilimab + Fruquinitinib + S-1 plus nab-paclitaxel
Product
Sintilimab + S-1 + nab-paclitaxel
Clinical trial
The Efficacy and Safety of Anti-PD-1 Combined With Thymosin and SOX in Neoadjuvant Treatment of cStage IIII Gastric or Esophagogastric Junctional Adenocarcinoma: A Prospective, Open-label, Single-arm, Phase II Clinical Study
Status: Not yet recruiting, Estimated PCD: 2027-06-01
Product
Anti-PD-1 Combined with Thymosin and SOX
Clinical trial
A Real-World Study of Neoadjuvant/Conversion Therapy for Locally Advanced or Metastatic Gastric Cancer With Chemotherapy Combined With Immune Checkpoint Inhibitors and Anti-Angiogenic Targeted Agents
Status: Not yet recruiting, Estimated PCD: 2026-03-31
Abstract
https://www.abstractsonline.com/pp8/#!/10517/presentation/20266
Product
olaparib + ramucirumab
Abstract
https://www.abstractsonline.com/pp8/#!/10828/presentation/10421
Product
sintilimab
Product
sintilimab + chemotherapy
Abstract
https://www.abstractsonline.com/pp8/#!/20272/presentation/11423
Product
cadonilimab
Clinical trial
Synergistic Effects of PD-1 Antibody and Chemotherapy Followed by Surgery in Patients With Limited-metastatic Gastric or Gastroesophageal Adenocarcinoma: an Open-label, Single-center, Phase 2 Trial (ROSETTE Trial)
Status: Not yet recruiting, Estimated PCD: 2027-07-01
Product
PD-1 Monoclonal Antibody
Clinical trial
Nordic Gastric and Esophageal Tumor Study
Status: Completed, Estimated PCD: 2022-12-28
Clinical trial
Phase II Study of Neoadjuvant Adebrelimab, Docetaxel, Oxaliplatin, and S-1 in Patients With Resectable Advanced Gastric Cancer
Status: Recruiting, Estimated PCD: 2025-05-20
Product
Adebrelimab
Clinical trial
A Phase I/II, Open-Label, Nonrandomized, Dose-Finding Safety, Tolerance, Pharmacokinetic, and Efficacy Study of Orally Administered S-1 in Combination With Cisplatin in Patients With Advanced Gastric Cancer
Status: Completed, Estimated PCD: 2006-03-01
Clinical trial
An Open-Label Multicenter, Randomized, Phase 3 Study of S-1 in Combination With Cisplatin Against 5-Fu in Combination W/ Cisplatin in Patients W/ Advanced Gastric Cancer Previously Untreated W/ Chemotherapy for Advanced Disease
Status: Completed, Estimated PCD: 2008-03-01
Product
S-1/Cisplatin
Product
5-FU/cisplatin
Clinical trial
A Multi-center, Phase IV, Extension Study in PEGASUS-D Trial to Evaluate Efficacy of Ursodeoxycholic Acid (UDCA) for the Prevention of Gallstone Formation After Gastrectomy in Patients With Gastric Cancer
Status: Completed, Estimated PCD: 2022-10-28
Product
UDCA
Clinical trial
A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer
Status: Recruiting, Estimated PCD: 2025-10-01
Drug
apatinib
Clinical trial
Prospective, Phase II Clinical Study of Short Course Radiotherapy With Sequential Disitamab Vedotin Combined With S-1 and Sintilimab as Whole Course Neoadjuvant Therapy for HER2 Expressed Locally Progressive Gastric Cancer
Status: Recruiting, Estimated PCD: 2026-05-31
Clinical trial
A Phase II Trial of Avutometinib in Combination With Defactinib in Metastatic Diffuse Gastric Cancer
Status: Recruiting, Estimated PCD: 2028-11-30
Drug
Avutometinib
Drug
Defactinib
Clinical trial
Predicting the Efficacy of Paclitaxel Plus Ramucirumab in Advanced Gastric Cancer.
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Predicting Peripheral Neuropathy of Paclitaxel in Second-line Chemotherapy for Gastric Cancer
Status: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
A Single Arm, Multicenter Phase II Clinical Study of TQB2450 (PD-L1 Inhibitor) Plus Anlotinib Combined With Oxaliplatin, Capecitabine in the First-line Treatment of Advanced Gastric Cancer (GC) or Adenocarcinoma of Esophagogastric Junction (AEG)
Status: Active (not recruiting), Estimated PCD: 2024-12-01
Product
TQB2450
Product
Pemetrexed